AstraZeneca Success On Prostate Cancer Drug Lowers Enthusiasm For Clovis

Positive top-line results from a competitor’s prostate cancer drug trial led Bank of America to downgrade Clovis Oncology Inc (NASDAQ: CLVS).

The Analyst

Bank of America's Tazeen Ahmad downgraded Clovis Oncology from Buy to Neutral while lowering the price target from $13 to $7.